News | Contrast Media | January 30, 2017

IV Contrast for CT Not Associated with Increased Risk of Acute Kidney Injury

Controlled study finds injury risk is actually higher for patients receiving unenhanced CT or not receiving CT at all

CT, computed tomography, IV contrast media, acute kidney injury risk, Annals of Emergency Medicine study

January 30, 2017 — Intravenous contrast media (typically iohexol or iodixanol) used in computed tomography (CT) does not appear to be associated with chronic kidney disease, dialysis, kidney transplant or acute kidney injury, despite long-held fears to the contrary. The results of the largest controlled study of acute kidney injury following contrast media administration in the emergency department were published online in Annals of Emergency Medicine ("Risk of Acute Kidney Injury Following Intravenous Contrast Media Administration").

"Over 80 million doses of IV contrast media are administered every year, and in the emergency department it can be essential to accurately diagnose certain acute critical conditions," said lead study author Jeremiah Hinson, M.D., Ph.D., of Johns Hopkins University School of Medicine in Baltimore. "But physicians have had concerns that the contrast media causes serious kidney problems later on, with some studies showing contrast-induced nephropathy occurring in as many as 14 percent of patients receiving it. However, studies used to establish this risk were performed prior to the development of modern contrast reagents or without adequate controls. Using a controlled design in current context, we could not find an association between intravenous contrast media use and acute kidney injury."

Researchers studied five years of records for patients receiving CT with or without contrast-enhancement in the emergency department. Of all CT scans, 57.2 percent were contrast-enhanced. The probability of developing acute kidney injury was 6.8 percent for patients undergoing contrast-enhanced CT, 8.9 percent for patients receiving unenhanced CT and 8.1 percent for patients not receiving CT at all.

"While a well-controlled randomized prospective study is required to fully determine the contribution of intravenous contrast media to the development of acute kidney injury, our results clearly demonstrate that in emergency departments such as ours where practice patterns have evolved to protect patients' kidneys, contrast media is not associated with increased risk of kidney injury," said Hinson. "Our data also suggest that in cases where contrast-enhanced CT is indicated to avoid delayed or missed diagnosis of critical disease, the potential morbidity and mortality resulting from a failure to diagnose potentially life-threatening conditions likely outweigh any potential risk of kidney injury.”

For more information: www.annemergmed.com

Hinson, J.S., Ehmann, M.R., Fine, D.M., Fishman, E.K., et al. "Risk of Acute Kidney Injury After Intravenous Contrast Media Administration," Annals of Emergency Medicine. Published Jan. 25, 2017. DOI: http://dx.doi.org/10.1016/j.annemergmed.2016.11.021


Related Content

News | Contrast Media

August 17, 2023 — University of Missouri School of Medicine neurologist Adnan Qureshi, MD recently led a study that ...

Home August 17, 2023
Home
News | Contrast Media

July 3, 2023 — According to an accepted manuscript published in ARRS’ own American Journal of Roentgenology (AJR) ...

Home July 03, 2023
Home
News | Contrast Media

May 11, 2021 — The American Institute of Ultrasound in Medicine (AIUM) and the American Society of Echocardiography (ASE ...

Home May 11, 2021
Home
Technology | Contrast Media

July 15, 2019 — The U.S. Food and Drug Administration (FDA) has approved Gadavist injection for use in cardiac magnetic ...

Home July 15, 2019
Home
Videos | Contrast Media

Sharon Mulvagh, M.D., FASE, FACC, FRCPC, professor of medicine, division of cardiology, Dalhousie University, Halifax ...

Home June 28, 2019
Home
Feature | Contrast Media | Dave Fornell, Editor

Iodine-based contrast agents used in computed tomography (CT) and catheter-based angiography have been implicated as a ...

Home May 31, 2019
Home
News | Contrast Media

May 9, 2019 — Osprey Medical announced the launch of DyeMINISH, a global patient registry to evaluate the ongoing safety ...

Home May 09, 2019
Home
News | Contrast Media

November 30, 2018 — VigiLanz and Cincinnati Children’s Hospital Medical Center recently announced a collaboration that ...

Home November 30, 2018
Home
News | Contrast Media

In February 2018, a workshop was held at the National Institutes of Health (NIH) in Bethesda, Maryland, to explore ...

Home September 12, 2018
Home
News | Contrast Media

January 19, 2018 — Ligand Pharmaceuticals Inc. announced initiation of a program to develop contrast agents with reduced ...

Home January 19, 2018
Home
Subscribe Now